REMARKS

Upon entry of this preliminary amendment, claims 4, 5, 6 and 7 are amended.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Amendment, or credit any overpayment to Deposit Account No. 50-0436.

In the event that an extension of time is required, or may be required in addition to that requested in a petition for an extension of time, the Commissioner is hereby requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

Gilberto M. Villacorta, Ph.D.
Reg. No. 34,038

Corinne M. Pouliquen
Reg. No. 35,753

Hamilton Square
600 Fourteenth Street, N.W.
Washington, DC 20005
Phone: (202) 220-1200
Fax: (202) 220-1201
Date: May 4, 2001

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The claims are amended as follows.

4. (Amended) The anti-virus agent according to [any of the proceeding claims] claim 1, wherein the regulatory region comprises [the] a Shine-Dalgarno sequence or an [the] internal ribosomal binding site (IRBS) of the genomic RNA of the poliovirus vaccine strain Sabin 2.

5. (Amended) The anti-virus agent according to [any of the proceeding claims] claim 1, wherein the toxin is selected from the group comprising diptheria exotoxin, diptheria exotoxin A-subunit, Sigella toxin and Disenteria toxin.

6. (Amended) The anti-virus agent according [any of the proceeding claims] claim 1, which comprises a DNA or a RNA vector.

7. (Amended) [Use of an anti-virus agent according to any of the proceeding claims for the manufacture of a medicament for] A method of treating a viral disease comprising the step of administering a therapeutically effective amount of the anti-virus agent of claim 1 in a pharmaceutically acceptable carrier.